Embryonic stem cells are cells harvested from very early-stage embryos that can become virtually any cell type in the human body. They come from a structure called the inner cell mass, a small cluster of cells inside the blastocyst, which is the hollow ball of cells that forms roughly five days after fertilization. Their purpose in nature is to give rise to all the tissues and organs of a developing organism. In the lab, researchers exploit that same versatility to study human development, model diseases, screen drugs, and explore cell-based therapies for conditions that currently have no cure.
Where Embryonic Stem Cells Come From
When a fertilized egg divides over several days, it eventually forms a blastocyst, a sphere with an outer shell of cells and an inner clump known as the inner cell mass (ICM). The outer shell will become the placenta; the inner cell mass will become the embryo itself. Embryonic stem cells (ESCs) are derived by isolating that inner cell mass and growing the cells in a lab dish under conditions that keep them in their undifferentiated state indefinitely.1PubMed Central. Transition of inner cell mass to embryonic stem cells: mechanisms, facts, and hypotheses When cultivated this way, the pluripotent cells from the ICM can be maintained and expanded as stable cell lines.2PubMed Central. Blockage of the Epithelial-to-Mesenchymal Transition Is Required for Embryonic Stem Cell Derivation
One thing worth knowing is that ESCs in the lab are not identical to the ICM cells they originated from. The process of growing them in culture changes certain features. For instance, telomeres, the protective caps on the ends of chromosomes, are longer in established ESC lines than they are in the original ICM, suggesting that extended culture selects for or induces traits the embryo’s own cells don’t naturally have.3PubMed Central. Different telomere-length dynamics at the inner cell mass versus established embryonic stem (ES) cells So ESCs are best understood as a lab-adapted version of early embryonic cells, close relatives of the ICM but not perfect copies.
What Makes Them Pluripotent
The defining feature of embryonic stem cells is pluripotency: the ability to differentiate into cells from all three germ layers of the body. Those germ layers, ectoderm, mesoderm, and endoderm, collectively give rise to every tissue type, from neurons to muscle to gut lining. Researchers have mapped the genes essential for these transitions using loss-of-function screens, and the picture that emerges is a tightly coordinated set of gene circuits that must be switched on or off in precise combinations to push cells toward one fate or another.4PubMed. Mapping Gene Circuits Essential for Germ Layer Differentiation via Loss-of-Function Screens in Haploid Human Embryonic Stem Cells
At the heart of this system are three key proteins: Oct4, Sox2, and Nanog. These act as master regulators, binding to thousands of genes across the genome and working together to keep the cell in its undifferentiated state.5PubMed Central. The transcriptional foundation of pluripotency Oct4 and Nanog share many of the same gene targets, and when researchers disrupted the genes those regulators control, the cells started differentiating, confirming that this network actively prevents the cell from committing to a specific identity.6Nature Genetics. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells External signals from the cell’s environment feed into this internal circuitry, and together they determine whether the cell self-renews or begins to specialize.7PubMed Central. Molecular basis of embryonic stem cell self-renewal: from signaling pathways to pluripotency network
There is also an important layer of control beyond the genes themselves. ESCs carry what are called bivalent marks on the packaging around their DNA. Certain chemical tags simultaneously silence developmental genes and keep them ready for rapid activation. When the cell receives the right differentiation signal, those genes can flip on quickly. This arrangement is especially common in ESCs compared to more mature cell types, and it is thought to be one reason stem cells can pivot so rapidly toward different fates.8PubMed. A bivalent chromatin structure marks key developmental genes in embryonic stem cells That said, the idea that every bivalently marked gene is neatly “poised” for activation may be too simple. Some of those genes may just be flickering at low levels as the cell samples multiple developmental programs at once, rather than sitting in a precisely balanced ready state.9PubMed Central. Generation of bivalent chromatin domains during cell fate decisions
Naïve Versus Primed States
Not all pluripotent cells are in the same developmental “gear.” Researchers distinguish between a naïve state, which resembles the earliest inner cell mass, and a primed state, which resembles cells slightly later in development, after the embryo has implanted in the uterine wall. Mouse ESCs grown under standard conditions tend to sit in the naïve state, while conventional human ESC lines more closely resemble the primed state.10PubMed Central. Epigenetic differences between naïve and primed pluripotent stem cells The practical difference matters: naïve cells can be injected into an early embryo and contribute to its development, while primed cells cannot, even though both are technically pluripotent.11PubMed. Naive and primed pluripotent states Recent work has focused on pushing human ESCs back into a more naïve-like state, which could open up research avenues that are currently only possible with mouse cells.
Medical Applications Already in Trials
The reason embryonic stem cells attract so much attention is their potential to replace damaged or lost cells in the body. Several clinical trials have now moved from animal experiments to human patients.
One of the earliest and most closely watched programs involved vision loss. In a pair of phase 1/2 trials in the United States, researchers transplanted retinal pigment epithelium cells derived from human ESCs into the eyes of 18 patients with either Stargardt’s macular dystrophy or age-related macular degeneration. Over the medium term, there was no evidence of dangerous cell overgrowth or immune rejection related to the transplant, and visual acuity improved in the majority of treated eyes while untreated fellow eyes did not show similar gains.12The Lancet. Human embryonic stem cells successfully transplanted in patients with Stargardt’s macular dystrophy and atrophic age-related macular degeneration: interim results of two prospective phase 1/2 trials Those results were described as the first evidence of medium- to long-term safety and possible biological activity of pluripotent-stem-cell-derived cells in any human disease.
Parkinson’s disease is another major target. The illness destroys dopamine-producing neurons in the brain, and the idea is to grow replacement neurons from ESCs and transplant them. Early animal work showed that ESC-derived dopamine neurons, when transplanted into rats with Parkinson’s-like symptoms, restored motor function in a gradual and sustained way.13PubMed Central. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model More recently, a phase 1/2 human trial reported that brain imaging showed signs of graft survival, with dopamine-related uptake increasing in the grafted brain regions compared to baseline. Participants who received a higher dose showed larger increases.14Nature Medicine. Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial
Diabetes has also drawn considerable effort. Researchers have coaxed both mouse and human ESCs into insulin-producing cells that respond to glucose. In mice with chemically induced diabetes, transplantation of these cells normalized blood sugar and kept the animals alive.15PubMed. Inducing embryonic stem cells to differentiate into pancreatic beta cells by a novel three-step approach with activin A and all-trans retinoic acid Protocols for generating human beta-like cells from ESCs continue to be refined, with the goal of producing a reliable, scalable supply of insulin-secreting cells for people with insulin-dependent diabetes.16PubMed Central. A differentiation protocol for the generation of pancreatic beta-like cells from human embryonic stem cells
Disease Modeling and Drug Discovery
Transplanting cells into patients is the headline application, but much of the day-to-day work with embryonic stem cells happens in labs studying disease and screening drugs. Because ESCs can be steered into many cell types, researchers use them to grow miniature organ-like structures called organoids. These three-dimensional clusters can mimic the architecture and function of real tissues, including the brain, liver, gut, and lungs.17PubMed Central. Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation
Lung organoids, for example, have been generated from human ESCs that contain multiple cell types found in real lungs, including ciliated cells and cells that produce surfactant. These can be infected with viruses or exposed to toxins to study how disease unfolds in human tissue without needing human subjects.18PubMed Central. Generation of Complete Multi-Cell Type Lung Organoids From Human Embryonic and Patient-Specific Induced Pluripotent Stem Cells for Infectious Disease Modeling and Therapeutics Validation The same logic applies to drug screening: you can test thousands of candidate compounds on human-derived cells in a dish before ever moving into animal testing, catching toxic or ineffective drugs earlier in the pipeline.19PubMed Central. Embryonic stem cell application in drug discovery
The Teratoma Problem
For all their promise, embryonic stem cells carry a significant safety risk: if even a small number of undifferentiated cells sneak into a therapeutic product, they can form teratomas, tumors that contain a disorganized jumble of tissues from all three germ layers. In animal experiments, as few as two ESC colonies mixed into a transplant were enough to produce a teratoma.20PubMed. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies Even cell preparations that had been differentiated into specific cell types, such as beating heart cells or insulin-secreting cells, still formed teratomas when transplanted, suggesting that purification protocols must be extremely thorough.20PubMed. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies
One strategy to manage this risk is to engineer a “suicide gene” into the stem cells. If residual undifferentiated cells begin forming a tumor, activating this genetic kill switch destroys them.21Journal of Biological Chemistry. Targeted deletion of tumor risk associated with human embryonic stem cells by a suicide gene Researchers view this as a safety net rather than a primary solution; the goal is still to remove undifferentiated cells before transplantation, but having a backup in place adds a layer of protection.
How Induced Pluripotent Stem Cells Compare
In 2006, a landmark study showed that ordinary adult cells, like skin cells, could be reprogrammed into a pluripotent state by introducing just four genes, Oct3/4, Sox2, Klf4, and c-Myc, producing what are called induced pluripotent stem cells (iPSCs).22PubMed. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors These iPSCs look and behave much like embryonic stem cells, can form all three germ layers, and can even contribute to embryonic development when injected into mouse blastocysts.23PubMed. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts Because iPSCs can be made from a patient’s own cells, they sidestep the ethical concerns associated with using embryos and, in theory, reduce immune rejection.
But the two cell types are not identical. iPSCs retain residual chemical marks from whatever tissue they originally came from, a kind of epigenetic memory that biases them toward differentiating back into related cell types while making it harder to push them toward unrelated ones.24PubMed Central. Epigenetic memory in induced pluripotent stem cells This memory fades with extended time in culture but can be an issue in early-passage iPSC lines. More recent work confirms the same pattern: iPSCs derived from different source tissues carry distinct residual gene expression and epigenetic signatures.25PubMed Central. Source cell-type epigenetic memory persists in induced pluripotent cells but is lost in subsequently derived germline cells Overall, the differences in gene activity, epigenetic landscape, differentiation potential, and mutation burden between ESCs and iPSCs are real, even if they are small.26PubMed. Induced pluripotent stem cells versus embryonic stem cells: close enough or yet too far apart? For some applications, those differences don’t matter. For others, especially where you need the cleanest possible starting material, ESCs remain the reference standard.
iPSCs also carry teratoma risk. Injecting even a modest number of iPSCs intravenously into mice led to tumor formation in multiple sites, with a tendency to appear in the nervous system.27PubMed Central. Evaluation and Control of Teratoma Risk in Hematology So while iPSCs solve some problems that ESCs present, they bring their own set of challenges.
The Immune Rejection Hurdle
Any cell transplanted from one person to another faces the immune system, which recognizes foreign tissue and tries to destroy it. ESC-derived therapies are no exception. Because the cells come from donor embryos, not from the patient, the recipient’s immune system will usually treat them as invaders. The retinal trials mentioned earlier used immunosuppressive drugs and benefited from the eye being a relatively immune-privileged site, but that approach won’t scale to every organ.
One promising strategy involves using gene-editing tools to knock out the surface molecules that flag cells as foreign. The idea is to create “universal” donor cells that could be transplanted into anyone without triggering rejection. But deleting those molecules introduces a new problem: cells that lack the usual surface markers can activate a different branch of the immune system, natural killer cells, which are primed to attack cells that look suspiciously bare.28Communications Biology. Immunological considerations and challenges for regenerative cellular therapies Researchers are now trying to thread the needle, removing enough surface markers to evade one arm of the immune response while adding signals that keep the other arm from attacking.29PubMed Central. Immune Editing: Overcoming Immune Barriers in Stem Cell Transplantation
The Ethics Landscape
Embryonic stem cell research has been controversial since its inception because deriving ESC lines typically requires destroying a human blastocyst. The moral status of that blastocyst is where opinions diverge. Some people and traditions hold that life begins at fertilization and that any destruction of a blastocyst is ethically unacceptable. Others argue that a five-day-old cluster of cells, before any nervous system development, does not have the same moral weight as a more developed embryo or a person.
Policies vary widely around the world. Some countries ban the creation of new ESC lines entirely, others allow it under strict oversight using surplus embryos from fertility clinics, and still others permit a broader range of embryo research. The legal and ethical frameworks remain fragmented and are evolving as the science moves faster than regulators can keep up.30PubMed Central. Advancements in Human Embryonic Stem Cell Research: Clinical Applications and Ethical Issues The arrival of iPSCs reduced some of the political pressure, since they don’t require embryos, but it didn’t eliminate it. ESCs remain the gold standard for many research questions, and newer technologies like embryoids, lab-grown structures that mimic aspects of early embryonic development, are raising fresh ethical and regulatory questions of their own.31PubMed Central. Ethical, legal, regulatory, and policy issues concerning embryoids: a systematic review of the literature
Growing Stem Cells at Scale
Turning embryonic stem cells into therapies for thousands of patients requires growing them in enormous quantities while maintaining their quality. Early ESC cultures depended on layers of mouse feeder cells and animal-derived coatings, which introduced the risk of contamination with non-human biological material. That was acceptable for basic research but a problem for any product destined for human patients. Over the past decade, the field has shifted toward fully defined, synthetic culture systems and bioreactors that can expand ESCs without any animal-derived ingredients.32PubMed Central. Concise review: The evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings Combining these synthetic coatings with three-dimensional bioreactor culture is expected to enable the large-scale production needed for clinical use, though standardization and cost remain works in progress.
The manufacturing challenge is sometimes overlooked in discussions about stem cell therapy, but it is one of the biggest practical bottlenecks. A single patient’s dose of cells for a retinal transplant is tiny; a dose for Parkinson’s disease is larger; and a dose for diabetes or heart failure could be orders of magnitude bigger. Scaling up production without sacrificing the cells’ quality or safety is an engineering problem as much as a biological one, and it is far from solved.